In 2025, Cspc Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Cspc Pharmaceutical Group has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 201,265.7a | 474,567.04a | 663,224b | |
Total Scope 2 | ||||
Unspecified Calculation Method | 853,794.57a | 493,310a | 418,037b | |
Total Scope 3 | 1,419,320.4a | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 54.181a | 119.3908a | 149.8733b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Cspc Pharmaceutical Group amounted to 1,055,060.27 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Cspc Pharmaceutical Group increased by 9.01%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Cspc Pharmaceutical Group were 201,265.7 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Cspc Pharmaceutical Group's Scope 1 emissions have decreased by 42.29%, reflecting a declining long-term trend in Scope 1 emissions over time.ac
Compared to the previous year (2024), Cspc Pharmaceutical Group's Scope 1 emissions decreased by 57.59%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Cspc Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 853,794.57 tCO₂e without specifying the calculation method.a
Since 2020, Cspc Pharmaceutical Group's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 22.18%, reflecting a rising long-term trend in Scope 2 emissions over time.ac
Compared to the previous year (2024), Cspc Pharmaceutical Group's Scope 2 emissions (Unspecified Calculation Method) rose by 73.07% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2025, Cspc Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.a
In 2025, Cspc Pharmaceutical Group reported 1,419,320.4 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Cspc Pharmaceutical Group includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2024, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2025, Cspc Pharmaceutical Group reported total Scope 3 emissions of 1,419,320.4 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 99.15% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.85% came from downstream activities like product use, distribution, and end-of-life treatment.a
In 2025, Cspc Pharmaceutical Group reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2025, the largest contributors to Cspc Pharmaceutical Group's Scope 3 emissions were:a
In 2025, Cspc Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 201,265.7 tCO₂e and total revenues of USD 3,715 millions. This translates into an emissions intensity of 54.18 tCO₂e per millions USD.a
In 2025, Cspc Pharmaceutical Group reported a Scope 1 emissions intensity of 54.18 tCO₂e per millions USD. Compared to the peer group median of 5.15, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, Cspc Pharmaceutical Group ranked 25 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Cspc Pharmaceutical Group among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2025, Cspc Pharmaceutical Group reported a total carbon footprint of 2,474,380.67 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 155.65% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Cspc Pharmaceutical Group's total carbon footprint was Scope 3 emissions, accounting for 57.36% of the company's total carbon footprint, followed by Scope 2 emissions at 34.51%.a